|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5698671A
(en)
|
1989-03-21 |
1997-12-16 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Metalloproteinase peptides
|
|
DE69033982T2
(de)
*
|
1989-03-21 |
2002-10-24 |
The United States Of America, Represented By The Secretary |
Matrizenmetalloproteinase-inhibitor-peptide
|
|
US6797492B2
(en)
|
1991-05-17 |
2004-09-28 |
Merck & Co., Inc. |
Method for reducing the immunogenicity of antibody variable domains
|
|
CA2103059C
(en)
|
1991-06-14 |
2005-03-22 |
Paul J. Carter |
Method for making humanized antibodies
|
|
JP3017591B2
(ja)
|
1992-01-17 |
2000-03-13 |
富士薬品工業株式会社 |
抗ヒトｔｉｍｐ−２モノクローナル抗体の製法およびその利用
|
|
US6562596B1
(en)
|
1993-10-06 |
2003-05-13 |
Amgen Inc. |
Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
|
|
DE69637481T2
(de)
|
1995-04-27 |
2009-04-09 |
Amgen Fremont Inc. |
Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
|
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
|
|
US6391265B1
(en)
|
1996-08-26 |
2002-05-21 |
Biosite Diagnostics, Inc. |
Devices incorporating filters for filtering fluid samples
|
|
ES2301183T3
(es)
|
1996-12-03 |
2008-06-16 |
Amgen Fremont Inc. |
Anticuerpo completamente humano que se une al receptor del egfr.
|
|
US6045899A
(en)
|
1996-12-12 |
2000-04-04 |
Usf Filtration & Separations Group, Inc. |
Highly assymetric, hydrophilic, microfiltration membranes having large pore diameters
|
|
WO1999004267A2
(en)
|
1997-07-16 |
1999-01-28 |
Charm Sciences, Inc. |
Test device and method for detecting an analyte in a sample
|
|
AU3185199A
(en)
|
1998-03-16 |
1999-10-11 |
Quidel Corporation |
Immunoassay device and method
|
|
US7214542B2
(en)
|
2003-01-30 |
2007-05-08 |
Michael Hutchinson |
Method of processing assay test results
|
|
WO2004096832A2
(en)
|
2003-04-29 |
2004-11-11 |
Children's Medical Center Corporation |
Novel antiangiogenic peptides
|
|
CN1833169A
(zh)
|
2003-08-11 |
2006-09-13 |
协和梅迪克斯株式会社 |
测量对象物测量器具、测量装置和测量方法
|
|
CN1993619A
(zh)
|
2004-07-28 |
2007-07-04 |
弗·哈夫曼-拉罗切有限公司 |
作为β细胞衰竭靶标/标志的TIMP－2
|
|
US7485468B2
(en)
|
2004-10-15 |
2009-02-03 |
Galapagos Bv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
|
|
WO2007048102A2
(en)
|
2005-10-18 |
2007-04-26 |
The Government Of The United States, As Represented By The Secretary Of Health And Human Services |
Angio-inhibitory peptides derived from human timp-2
|
|
CA2740788C
(en)
|
2008-10-21 |
2023-03-14 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
|
US8900881B2
(en)
|
2008-12-30 |
2014-12-02 |
Jin Po Lee |
Quantitative analyte assay device and method
|
|
DK2488203T3
(en)
*
|
2009-10-16 |
2017-03-13 |
Omeros Corp |
METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
|
|
ES2818138T3
(es)
|
2009-12-20 |
2021-04-09 |
Astute Medical Inc |
Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
|
|
RS54879B1
(sr)
|
2010-02-05 |
2016-10-31 |
Astute Medical Inc |
Metode i kompozicije za dijagnoze i prognoze oštećenja bubrega i bubrežne insuficijencije
|
|
CA2794721A1
(en)
|
2010-03-31 |
2011-10-13 |
Sekisui Medical Co., Ltd. |
Assay utilizing immunochromatography, immunochromatographic test strip, and assay reagent kit for immunochromatography
|
|
EP2585827A4
(en)
|
2010-06-23 |
2013-12-04 |
Astute Medical Inc |
METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency
|
|
AU2011307259A1
(en)
|
2010-09-30 |
2013-05-02 |
Nitto Denko Corporation |
Modulation of TIMP1 and TIMP2 expression
|
|
BR112014004389A2
(pt)
|
2011-08-26 |
2017-03-28 |
Astute Medical Inc |
métodos e composições para diagnóstico de lesão renal e insuficiência renal
|
|
EP2788759B1
(en)
|
2011-12-08 |
2019-02-20 |
Astute Medical, Inc. |
Methods and uses for diagnosis of renal injury and renal failure
|
|
CN104603150A
(zh)
|
2012-04-20 |
2015-05-06 |
中央研究院 |
与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体
|
|
WO2014031476A1
(en)
|
2012-08-21 |
2014-02-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
|
EP4105657B1
(en)
|
2013-01-17 |
2024-09-25 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
|
US20160146832A1
(en)
|
2013-06-05 |
2016-05-26 |
Lakhmir S. Chawla |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
|
CA2920521A1
(en)
|
2013-08-07 |
2015-02-12 |
Astute Medical, Inc. |
Assays for timp2 having improved performance in biological samples
|
|
EA201690731A1
(ru)
|
2013-11-06 |
2016-10-31 |
Астьют Медикал, Инк. |
Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах
|
|
CN110007084B
(zh)
|
2013-12-03 |
2022-11-18 |
阿斯图特医药公司 |
用于肾损伤和肾衰竭的诊断和预后的方法和组合物
|
|
KR101605421B1
(ko)
*
|
2014-03-05 |
2016-03-23 |
국립암센터 |
B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
|
|
WO2016164854A1
(en)
|
2015-04-09 |
2016-10-13 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
|
US11243217B2
(en)
|
2016-06-06 |
2022-02-08 |
Astute Medical, Inc. |
Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
|
|
US20190263926A1
(en)
|
2016-10-28 |
2019-08-29 |
Astute Medical, Inc. |
Use of Antibodies to TIMP-2 for the Improvement of Renal Function
|
|
US11346846B2
(en)
|
2017-02-06 |
2022-05-31 |
Astute Medical, Inc. |
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
|
|
EP3606554A4
(en)
|
2017-04-05 |
2020-12-09 |
Astute Medical, Inc. |
ASSAYS FOR TIMP2 WITH IMPROVED EFFICIENCY IN BIOLOGICAL SAMPLES
|
|
EP3621987A4
(en)
|
2017-05-07 |
2021-01-06 |
Astute Medical, Inc. |
USE OF INSULIN-SIMILAR GROWTH FACTOR-BINDING PROTEIN 7 AND A METALLOPROTEINASE 2 TISSUE INHIBITOR IN THE MANAGEMENT OF RENAL REPLACEMENT THERAPY
|